Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlzeCure Pharma ABFRA:AC6 -3.57%35 EV-to-EBIT is 27.47 as of Sep. 21, 2026, which is 11% above its 10-year median of 24.65. GuruFocus rates FRA:AC6 with a GF Score™ of 35/100. The stock has 5 warning signs investors should review. Among 381 Biotechnology companies, AlzeCure Pharma AB ranks worse than 68.5% on this metric.
AlzeCure Pharma AB (FRA:AC6) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AlzeCure Pharma AB's Enterprise Value for the quarter that ended in Jun. 2026 was €47.19 Mil.
AlzeCure Pharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AlzeCure Pharma AB EV-to-EBIT Related Terms
AlzeCure Pharma AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AlzeCure Pharma AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AC6 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, AlzeCure Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AlzeCure Pharma AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AlzeCure Pharma AB's EV-to-EBIT falls into.
AlzeCure Pharma AB's current Enterprise Value is €77.87 Mil.
AlzeCure Pharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AlzeCure Pharma AB (FRA:AC6) has a EV-to-EBIT of 27.47 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AlzeCure Pharma AB and its competitors. This is 11% above median its historical median of 24.65. Over the past decade, AlzeCure Pharma AB's EV-to-EBIT has ranged from 22.06 to 30.00. According to the industry distribution chart, AlzeCure Pharma AB ranks #261 out of 381 companies in the Biotechnology industry, placing it in the top 68.5%.
Is AlzeCure Pharma AB's EV-to-EBIT too high?
AlzeCure Pharma AB's current EV-to-EBIT of 27.47 is 11% above median its 10-year median of 24.65. Over the past 10 years, this metric has ranged from a low of 22.06 to a high of 30.00. The Biotechnology industry median EV-to-EBIT is 14.12. AlzeCure Pharma AB's value of 27.47 is 94.5% above this industry median. Based on the distribution chart, AlzeCure Pharma AB ranks #261 out of 381 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AlzeCure Pharma AB has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AlzeCure Pharma AB ranks #261 out of 381 companies for EV-to-EBIT. This places AlzeCure Pharma AB in the lower half of its industry. The industry median EV-to-EBIT is 14.12. AlzeCure Pharma AB's value of 27.47 is 94.5% above this benchmark. Historically, AlzeCure Pharma AB's own EV-to-EBIT has ranged from 22.06 to 30.00 over the past decade. While the company's 10-year median is 24.65 vs. the industry median of 14.12, AlzeCure Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.12, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AlzeCure Pharma AB's current EV-to-EBIT of 27.47 is 94.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AlzeCure Pharma AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AlzeCure Pharma AB's current EV-to-EBIT is 27.47, which is 11% above median its own 10-year median of 24.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current EV-to-EBIT of 27.47. The current EV-to-EBIT is 27.47, which is 11% above median its 10-year median of 24.65 and 94.5% above the Biotechnology industry median of 14.12. AlzeCure Pharma AB's overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current EV-to-EBIT is 27.47 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
35GF Score
Get the complete analysis for FRA:AC6
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AC6 has been successfully added to your 
